alexa Selective Serotonin Reuptake Inhibitors, are They All Equal? A Pharmacoepidemiological Study
ISSN: 2167-1052

Advances in Pharmacoepidemiology and Drug Safety
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Selective Serotonin Reuptake Inhibitors, are They All Equal? A Pharmacoepidemiological Study

Péron E1,2, Hardouin JB2,3, Sébille V2,3, Feuillet F2,3, Wainstein L1,2, Chaslerie A4, Pivette J4, Jolliet P1,2 and Victorri-Vigneau C1,2*

1Centre for Evaluation and Information on Drug-Addictovigilance, Clinical Pharmacology, Hôtel Dieu, Institute of Biology, 9 Quai Moncousu, 44093, Nantes Cedex 1, France

2EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Health Measures, Faculty of Pharmaceutical and Biological Sciences, Nantes, France

3Biometrics Platform, Promoting Clinical Research Unit, CHU Nantes, France

4Regional Department of Health Insurance Medical Service of the Loire, Nantes, France

*Corresponding Author:
Caroline Victorri-Vigneau
Centre for Evaluation and Information on Drug - Addictovigilance Clinical Pharmacology
Hôtel Dieu, Institute of Biology
9 Quai Moncousu
44093 Nantes Cedex 1, France Tel: +33 240084096
Fax: +33 240084097
E-mail: [email protected]

Received date: May 23, 2016; Accepted date: June 28, 2016; Published date: June 30, 2016

Citation: Péron E, Hardouin JB, Sébille V, Feuillet F, Wainstein L, et al. (2016) Selective Serotonin Reuptake Inhibitors, are They All Equal? A Pharmacoepidemiological Study. Adv Pharmacoepidemiol Drug Saf 5:203. doi:10.4172/2167-1052.1000203

Copyright: © 2016 Péron E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: According to the French health authorities’ guidelines relative to depression and anxiety disorder treatments, six Selective Serotonin Reuptake Inhibitors are available for prescription as a first-line of treatment. The guidelines suggest equivalence between these treatment options, but studies diverge regarding efficacy and safety profiles. Moreover, conditions in clinical trials are strictly controlled and do not truly reflect real life utilization. The objective of this study was to evaluate differences in efficacy and/or safety between these six selective serotonin reuptake inhibitors in real conditions of use. Methods: Efficacy and safety were evaluated using a regional database of the French national health insurance. Patients who received a selective serotonin reuptake inhibitor for a new depressive disorder and who were compliant to the treatment for a period of at least 6 months were included. Events indicative of a lack of efficacy and/or safety during the 12-month follow-up period were identified in the database (i.e., a dose increase, a switch to another antidepressant drug or an association with another antidepressant drug). A Cox model was used to compare the frequency and the delay to onset of each type of indicative event for each selective serotonin reuptake inhibitor. Results: Out of 3542 patients included, 1081 (30.5%) experienced an indicative event. The Cox model showed differences in terms of efficacy and safety. Patients treated with paroxetine, sertraline or citalopram as a first antidepressant were more likely to present a therapeutic failure than those treated by escitalopram or fluoxetine. Conclusion: A Cox model identified differences between selective serotonin reuptake inhibitors in terms of efficacy and/or safety profile. Our study positioned Escitalopram as the most efficient and/or safe treatment option. This study strategy can viably be used to evaluate the real life usage and effects of other drugs, an essential part of post approval evaluation.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

biochemj[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords